Hari Anant Deshpande MD

Associate Professor of Medicine (Medical Oncology) and Assistant Professor of Surgery (Otolaryngology) and Assistant Clinical Professor of Nursing

Clinical Interests

Head and neck cancer; Genitourinary (GU) cancers; sarcomas; thyroid cancer.


Board Certifications

1998
Hematology (Internal Medicine), Board Certified
1999
Medical Oncology, Board Certified
1995
Internal Medicine, Board Certified

Patient Care Locations

hari_deshpandefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and PharynxRTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer {CIRB}
ProstateSWOG S1216: A PHASE III RANDOMIZED TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY + TAK-700 WITH ANDROGEN DEPRIVATION THERAPY + BICALUTAMIDE IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC HORMONE SENSITIVE PROSTATE CANCER
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck {CIRB}
Brain and Nervous System and Other Respiratory and Intrathoracic OrgansA randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma

More Clinical Trials...

Edit Profile